Photdynamic Therapy (PDT)
PreclinicalSmall molecule
Photdynamic Therapy (PDT) is one of 9 small molecule programs targeting Recurrent. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Recurrent
#DrugCompanyPhaseTrials
1Xiaflex
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Certolizumab
Johnson & JohnsonPhase 3
Lu-PSMA I&T
MMedical University of Vienna
Phase 2
Anti-PD-1 Monoclonal Antibody
IiTeos Therapeutics
Phase 1
Photofrin
PPinnacle Biologics Inc.
Preclinical
Cordarone
WWyeth-Lederle Vaccines
Preclinical
Ptvg-HP
UUniversity of Wisconsin, Madison
Phase 1
CART-EGFR-Il13ra2 Cells
UUniversity of Pennsylvania
Phase 1
Photdynamic Therapy (PDT)
RRoswell Park Cancer Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Photdynamic Therapy (PDT). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRoswell Park Cancer Institute